FDA Brief

Warning letters Drugs

FDA warning letter to

Texinkart Inc.

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

Texinkart Inc. sold four Ayurvedic products online without FDA drug approval, FDA says.

What happened

FDA reviewed Texinkart’s website https://texinkart.com/ in April 2026 and identified four products—Thathu Busti Lehyam, Baidyanath Prostaid Tablets, Rajpro Capsules, and Rathina Purush Capsules—with labeling claims to treat disease or affect body function. FDA says the products are drugs that need FDA approval and have no approved applications, so selling them in interstate commerce violates the Federal Food, Drug, and Cosmetic Act. This was a website review, not an inspection.

What FDA found

  1. FDA treats the four products as drugs because their website labeling claims they help with erectile dysfunction, prostate enlargement, sperm strength, semen concentration, sexual desire, or stamina.

    FD&C Act § 201(g)(1), 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. FDA says the products are new drugs because they are not generally recognized as safe and effective for their labeled uses.

    FD&C Act § 201(p), 21 U.S.C. 321(p)
  3. No FDA-approved applications are in effect for the products, so selling them in interstate commerce violates the unapproved new drug provisions.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. 355(a), 331(d)

What FDA wants

FDA tells Texinkart to investigate and determine root causes, implement corrective and preventive measures, and send a written response with specific steps and documentation to FDAAdvisory@fda.hhs.gov within 15 business days. The response must cite reference number 729046.

Who should pay attention

  • online retailers selling Ayurvedic or sexual-health products
  • companies making drug claims for supplements
  • regulatory teams reviewing website labeling and claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  4. Phuoc Loc Tho Herbals, Inc.

    FDA warned Phuoc Loc Tho Herbals that its herbal products are unapproved new drugs marketed with disease claims.

    High risk